Gemcitabine: Brands, Price & Uses in Bangladesh

Gemcitabine is a cytotoxic chemotherapy agent administered only under the supervision of an oncology specialist as part of a physician-directed cancer treatment protocol. Its use is classified by strength of evidence as follows:

Established / FDA-approved indications

• Pancreatic cancer: First-line treatment of locally advanced (non-resectable stage II or stage III) or metastatic adenocarcinoma of the pancreas, including patients previously treated with fluorouracil.
• Non-small cell lung cancer (NSCLC): First-line treatment of inoperable, locally advanced (stage IIIA or IIIB) or metastatic (stage IV) NSCLC, in combination with cisplatin.
• Breast cancer: In combination with paclitaxel, for metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
• Ovarian cancer: In combination with carboplatin, for advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

Guideline-supported / commonly used off-label indications

• Bladder (urothelial) cancer: In combination with cisplatin, as a guideline-recognised regimen for locally advanced or metastatic urothelial carcinoma, particularly when cisplatin-based standard regimens are not suitable.
• Biliary tract cancer (cholangiocarcinoma/gallbladder cancer): In combination with cisplatin, a guideline-supported regimen for advanced biliary tract cancers.
• Other malignancies such as soft-tissue sarcoma and malignant mesothelioma, used off-label in select cases based on oncologist judgment and institutional protocols.

The exact indication, combination partner, and treatment protocol for Gemcitabine are always determined by the treating oncologist based on cancer type, stage, and patient fitness.

Gemcitabine dosing, scheduling, and duration are determined solely by the treating oncologist based on the specific cancer type, combination regimen, body surface area (BSA), and the patient's hematologic and organ function. The information below reflects typical protocol-based regimens and is not intended for self-administration or dose selection by patients.

Administration

• Gemcitabine must be administered only as a slow intravenous infusion by a qualified oncology healthcare professional under close medical supervision; it is never given orally, intramuscularly, or self-administered at home.
• Standard infusion time is approximately 30 minutes; infusion times longer than 60 minutes or more frequent than weekly dosing have been associated with increased toxicity and are not recommended outside specific protocols.
• Doses are calculated by body surface area (BSA, mg/m²) and may be reduced, delayed, or withheld based on absolute neutrophil count, platelet count, and evidence of non-hematologic toxicity, as determined by the treating physician.
• Pre-medication (e.g. antiemetics) and monitoring of complete blood counts before each dose are part of standard protocol.

Renal/hepatic impairment

Gemcitabine should be used with caution and close monitoring in patients with pre-existing renal or hepatic impairment, as clearance may be reduced; specific validated dose-adjustment guidelines are not well established, so dosing in this setting is individualized by the oncologist, often with more frequent monitoring and dose reduction.

Side effects of Gemcitabine are common because it is a cytotoxic chemotherapy agent. Serious toxicities are covered fully under Precautions and Warnings; this section lists the overall frequency pattern.

Very common

• Myelosuppression (low white blood cell, platelet, and red blood cell counts) — see Precautions and Warnings
• Nausea and vomiting
• Elevated liver enzymes (transaminases, alkaline phosphatase)
• Flu-like symptoms (fever, chills, headache, myalgia, fatigue), usually within hours of infusion
• Rash and mild itching
• Hair thinning/hair loss (usually mild)
• Mild proteinuria and hematuria
• Peripheral edema

Less common but clinically important

• Diarrhea, stomatitis (mouth sores)
• Injection/infusion site reactions
• Constipation

Rare but serious (see Precautions and Warnings for full detail)

• Severe pulmonary toxicity (interstitial pneumonitis, pulmonary edema, capillary leak syndrome, ARDS)
• Hemolytic uremic syndrome (HUS) / thrombotic microangiopathy
• Severe hepatotoxicity including liver failure
• Posterior reversible encephalopathy syndrome (PRES)
• Severe skin reactions